Amarin Corporation PLC Stock News

AMRN earnings call for the period ending March 31, 2022.

Amarin Corporation plc (NASDAQ:AMRN ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Affairs Ka

Missed expectations on the top and bottom lines suggest Amarin's path forward isn't as clear as investors want it to be.

Amarin Corporation plc (NASDAQ: AMRN) shares are plunging after it said it would continue suspending 2022 revenue guidance and Q1 earnings came short of expectations. The update follows the ongoing g

DUBLIN, Ireland and BRIDGEWATER, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today its partner HLS Therapeutics has completed negotiations with Canada’s

Отмечает первое возмещение затрат на оценку технологий здравоохранения (HTA) в Европе и инициирует следующий �

Amarin is struggling to maintain growth as generics. It is banking on the European markets to drive growth in the coming years. Read to know why it's a Hold.

Amarin has had a rough go of it since the patent ruling in the United States for their flagship product, Vascepa. The company is struggling to maintain growth as generics. The company is banking on th

DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior m

There are a number of interesting developments at Amarin. These may enable Amarin to regain ground it lost due to an unconscionable court ruling a few years ago.

DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior manag

Новый субанализ постфактум знаменательного исследования REDUCE-IT, опубликованный в Journal of the American Heart Association (JAHA),

Experimental trial research presented at the American College of Cardiology’s 71st Annual Scientific Session showed that the combinations of EPA/atorvastatin active metabolite (ATM) and of EPA/rosuv

Mijlpaal voor eerste evaluatie van gezondheidstechnologie (HTA) voor vergoeding in Europa en start van de volgende fase van de groeistrategie van het bedrijf

Erste Health Technology Assessment (HTA)-Kostenerstattung in Europa leitet die nächste Phase der Wachstumsstrategie des Unternehmens ein